Novartis Fabhalta® (iptacopan) meets Phase III primary endpoint, slows kidney function decline in patients with IgA nephropathy (IgAN)

Novartis Fabhalta® (iptacopan) meets Phase III primary endpoint, slows kidney function decline in patients with IgA nephropathy (IgAN)
arcticnovartis

  • In APPLAUSE-IgAN final analysis, Fabhalta demonstrated statistically significant, clinically meaningful improvement in estimated glomerular filtration rate (eGFR) slope vs. placebo over two years1

  • eGFR is key marker of kidney function; IgAN is progressive autoimmune kidney disease that leads to kidney failure in many patients1-3 
/by

Novartis receives FDA approval for Rhapsido® (remibrutinib), the only oral, targeted BTKi treatment for chronic spontaneous urticaria (CSU)

Novartis receives FDA approval for Rhapsido® (remibrutinib), the only oral, targeted BTKi treatment for chronic spontaneous urticaria (CSU)
arcticnovartis

Ad hoc announcement pursuant to Art. 53 LR

/by

Novartis to Launch Direct-to-Patient Platform for Cosentyx® (secukinumab) in the US 

Novartis to Launch Direct-to-Patient Platform for Cosentyx® (secukinumab) in the US 
arcticnovartis

  • Select units of Cosentyx to be made available at 55% discount off list price on direct-to-patient (DTP) platform beginning November 1, 2025
/by

Novartis to Launch Direct-to-Patient Platform for Cosentyx® (secukinumab) in the US 

Novartis to Launch Direct-to-Patient Platform for Cosentyx® (secukinumab) in the US 
arcticnovartis

  • Select units of Cosentyx to be made available at 55% discount off list price on direct-to-patient (DTP) platform beginning November 1, 2025
/by

Novartis announces commencement of tender offer to acquire Tourmaline Bio

Novartis announces commencement of tender offer to acquire Tourmaline Bio
arcticnovartis

Basel, September 29, 2025 – Novartis today announced that Torino Merger Sub Inc., a Delaware corporation and an indirect wholly owned subsidiary of Novartis (“Purchaser”), has commenced a tender offer to acquire all of the outstanding shares of common stock, par value $0.0001 per share (the “Shares”), of Tourmaline Bio, Inc., a Delaware corporation (“Tourmaline”), at a price of $48 per Share, in cash, without interest and subject to any applicable withholding.

/by

Novartis announces commencement of tender offer to acquire Tourmaline Bio

Novartis announces commencement of tender offer to acquire Tourmaline Bio
arcticnovartis

Basel, September 29, 2025 – Novartis today announced that Torino Merger Sub Inc., a Delaware corporation and an indirect wholly owned subsidiary of Novartis (“Purchaser”), has commenced a tender offer to acquire all of the outstanding shares of common stock, par value $0.0001 per share (the “Shares”), of Tourmaline Bio, Inc., a Delaware corporation (“Tourmaline”), at a price of $48 per Share, in cash, without interest and subject to any applicable withholding.

/by

Bringing breakthroughs to more patients

Bringing breakthroughs to more patients
angilma1

/by

Bringing breakthroughs to more patients

Bringing breakthroughs to more patients
angilma1

/by

Novartis to showcase transformative data in advanced prostate and early breast cancer at ESMO 2025

Novartis to showcase transformative data in advanced prostate and early breast cancer at ESMO 2025
arcticnovartis

  • Key data from PSMAddition has been selected for a Presidential session; data to showcase the efficacy and safety of PluvictoTM plus standard of care (SoC) versus SoC alone in PSMA+ mHSPC
  • NATALEE five-year analysis of Kisqali® to provide further long-term insights into risk of recurrence reduction in a broad EBC patient population
/by

Novartis to showcase transformative data in advanced prostate and early breast cancer at ESMO 2025

Novartis to showcase transformative data in advanced prostate and early breast cancer at ESMO 2025
arcticnovartis

  • Key data from PSMAddition has been selected for a Presidential session; data to showcase the efficacy and safety of PluvictoTM plus standard of care (SoC) versus SoC alone in PSMA+ mHSPC
  • NATALEE five-year analysis of Kisqali® to provide further long-term insights into risk of recurrence reduction in a broad EBC patient population
/by